- Home
- SCNX vs LPTX Comparison
SCNX vs LPTX Comparison
Compare SCNX & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- LPTX
- Stock Information
- Founded
- SCNX 2010
- LPTX 2011
- Country
- SCNX United States
- LPTX United States
- Employees
- SCNX N/A
- LPTX N/A
- Industry
- SCNX Other Pharmaceuticals
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCNX Health Care
- LPTX Health Care
- Exchange
- SCNX Nasdaq
- LPTX Nasdaq
- Market Cap
- SCNX 31.5M
- LPTX 35.4M
- IPO Year
- SCNX 2020
- LPTX N/A
- Fundamental
- Price
- SCNX $0.82
- LPTX $0.42
- Analyst Decision
- SCNX
- LPTX Hold
- Analyst Count
- SCNX 0
- LPTX 1
- Target Price
- SCNX N/A
- LPTX N/A
- AVG Volume (30 Days)
- SCNX 63.1M
- LPTX 1.7M
- Earning Date
- SCNX 11-12-2025
- LPTX 11-13-2025
- Dividend Yield
- SCNX N/A
- LPTX N/A
- EPS Growth
- SCNX N/A
- LPTX N/A
- EPS
- SCNX N/A
- LPTX N/A
- Revenue
- SCNX $128,202.00
- LPTX N/A
- Revenue This Year
- SCNX N/A
- LPTX N/A
- Revenue Next Year
- SCNX N/A
- LPTX N/A
- P/E Ratio
- SCNX N/A
- LPTX N/A
- Revenue Growth
- SCNX N/A
- LPTX N/A
- 52 Week Low
- SCNX $0.46
- LPTX $0.22
- 52 Week High
- SCNX $8.81
- LPTX $3.92
- Technical
- Relative Strength Index (RSI)
- SCNX 48.09
- LPTX 42.57
- Support Level
- SCNX $0.69
- LPTX $0.43
- Resistance Level
- SCNX $1.10
- LPTX $0.56
- Average True Range (ATR)
- SCNX 0.34
- LPTX 0.06
- MACD
- SCNX -0.02
- LPTX -0.02
- Stochastic Oscillator
- SCNX 16.70
- LPTX 6.66
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.